Navigation Links
Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
Date:9/15/2008

d or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed with the SEC on March 14, 2008, as well as other filings by the company with the SEC.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet, Inc. undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
3. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
4. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
5. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
6. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
9. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
10. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
11. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  4WEB Medical announces the formal ... and ankle osteotomy implants on the market today ... annual meeting in Chicago .  The ... a surgeon,s osteotomy needs with 74 size options included in ... offerings of only 15 to 18 implant sizes, which ...
(Date:9/19/2014)... -- UBM Medica US announces that  OncoTherapy ... oncologists and other clinicians gain a better understanding of ... therapies and immunotherapies, discusses some of the latest news ... Every September, Blood Cancer Awareness Month is ... cancers—helping to increase survival rates and improve the quality ...
(Date:9/19/2014)... SOUTH EASTON, Mass. , Sept. 19, 2014 ... the "Company") today announced it has received and ... throughput Barozyme HT48 instruments and has begun to ... believes the first instrument will be ready for ... will be built and released at a rate ...
Breaking Medicine Technology:4WEB Medical Unveils 3D-Printed Osteotomy Truss System 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3
... 7, 2011 CareFusion Corporation (NYSE: ... today the appointment of Carlos M. Nunez, M.D. as its ... an anesthesiologist, intensivist and hospitalist as well as an experienced ... business career in the areas of clinical effectiveness, information technology, ...
... CHICAGO, March 7, 2011 General Nutrition Company (GNC) ... products manufacturer Sakar International for a line of more ... line,s initial merchandise offerings will range from heart rate ... and electronic pill boxes. The products ...
Cached Medicine Technology:CareFusion Appoints Carlos M. Nunez, M.D. as Chief Medical Officer 2GNC Teams With Sakar International for Branded Health and Wellness Product Line 2GNC Teams With Sakar International for Branded Health and Wellness Product Line 3
(Date:9/20/2014)... NV (PRWEB) September 21, 2014 ... method developed by fitness expert Michael Wren that has ... stubborn weight and reverse health conditions like high blood ... attention of Shane Michaels, prompting an investigative review. ... methods and tips upside down by showing people what ...
(Date:9/20/2014)... 2014 Villa del Palmar at the ... experience any damage in relation to Hurricane Odile and ... , Hurricane Odile struck Cabo San Lucas the night ... powerful surf conditions. Located on the east side of ... experienced some heavy rain, but no damage whatsoever to ...
(Date:9/20/2014)... 20, 2014 On Monday, September 22, ... pediatric cancer research grant from Hyundai Hope on Wheels ... Children’s Hospital located on 11234 Anderson St., in Loma ... Kimberley Payne, Associate Professor at Loma Linda University and ... leukemia in children. , Loma Linda University ...
(Date:9/20/2014)... Sept. 19, 2014 (HealthDay News) -- The avian flu ... 2011 could be spread through respiratory drops and therefore ... new study. Although no human illnesses have been ... Jude Children,s Research hospital have discovered natural mutations to ... to travel through the air in droplets. Current ...
(Date:9/20/2014)... New PharmaPoint Drug Evaluation report, “Symbicort ... The asthma market saw very slow growth over ... with relatively efficacious standard therapies, such as short-acting ... long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has ... launch of seven novel targeted biologic agents and ...
Breaking Medicine News(10 mins):Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 3Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 3Health News:Avian Flu In Harbor Seals Could Infect People 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4
... Harvard Graduate School of Education (HGSE) will ... leaders, practitioners and faculty improve educational practices through greater ... Brain, and Education institute will explore how advances ... functions can improve the educational process. Information about ...
... does speciation the evolutionary process that results in the formation ... contributed to our understanding of speciation? , Evolutionary biologist David ... will give at UC Riverside at 7 p.m., Thursday, April 30, ... title of his talk is "The Evolution of Evolution: Darwin Then ...
... sales in Russia, Brazil, and India will shrink by ... WALTHAM, Mass., April 23 According to Millennium ... markets in Brazil, India, and Russia, the global economic ... markets in these 3 countries in 2009, particularly for ...
... 23 Kendle (Nasdaq: KNDL ) announced ... financial results after the market closes on Wednesday, May ... call and simultaneous webcast on Thursday, May 7 at ... will follow.(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO ...
... Court for the District of Massachusetts has preliminarily approved ... large drug wholesaler. The lawsuit, called New ... concerns the pricing of more than 450 brand-name ... money back. Prescription drugs are ...
... facilities offering weight loss surgery, more people choosing ... offering surgical weight loss programs have increased dramatically ... important than ever to know which ones produce ... undergoing weight loss surgery at facilities designated as ...
Cached Medicine News:Health News:Bringing Brain Science to the Classroom 2Health News:How new species evolve is focus of public lecture at UC Riverside 2Health News:How new species evolve is focus of public lecture at UC Riverside 3Health News:Emerging Markets for Diagnostic Imaging Systems Hurt by Economic Crisis 2Health News:Kendle Announces First Quarter 2009 Earnings Conference Call and Webcast 2Health News:Proposed $350 Million Class Action Settlement Regarding Drug Pricing Provides Consumers and Third-Party Payors With Money Back 2Health News:Patients Had Fewer Infection Rates, Fewer Complications at Blue Distinction Centers for Bariatric Surgery(R), According to HealthCore Study 2Health News:Patients Had Fewer Infection Rates, Fewer Complications at Blue Distinction Centers for Bariatric Surgery(R), According to HealthCore Study 3Health News:Patients Had Fewer Infection Rates, Fewer Complications at Blue Distinction Centers for Bariatric Surgery(R), According to HealthCore Study 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: